Financhill
Buy
58

VCYT Quote, Financials, Valuation and Earnings

Last price:
$26.59
Seasonality move :
12.52%
Day range:
$25.85 - $26.92
52-week range:
$19.73 - $47.32
Dividend yield:
0%
P/E ratio:
64.98x
P/S ratio:
4.55x
P/B ratio:
1.75x
Volume:
634.2K
Avg. volume:
1M
1-year change:
27.04%
Market cap:
$2.1B
Revenue:
$445.8M
EPS (TTM):
$0.41

Earnings Data

Next earnings date for VCYT
Aug 06
2025
Most recent earnings per share
$0.09
Missed by $0.11
(May 7/2025)
Consensus Estimate
$0.20
(May 7/2025)

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

VCYT Quarterly Earnings History

Date Quarter Revenue Forecast Actual Revenue Reported EPS Consensus EPS Beat/Miss
08/06/2025 Q2 $120.9M -- -- $0.30 --
05/07/2025 Q1 $111M $114.5M $0.09 $0.20 -$0.11
02/24/2025 Q4 $116.7M $118.6M $0.06 $0.26 -$0.20
11/06/2024 Q3 $109.8M $115.9M $0.19 $0.17 $0.02
08/06/2024 Q2 $100.2M $114.4M $0.07 -$0.01 $0.08
05/07/2024 Q1 $93.4M $96.8M -$0.02 -$0.10 $0.08
02/22/2024 Q4 $92.8M $98.2M -$0.39 -$0.05 -$0.34
11/07/2023 Q3 -- -- -$0.41 -$0.13 -$0.28
08/08/2023 Q2 -- -- -$0.12 -$0.14 $0.02
05/04/2023 Q1 -- -- -$0.11 -$0.11 -$0.00
02/22/2023 Q4 -- -- -$0.05 -$0.08 $0.03
11/02/2022 Q3 -- -- -$0.12 -$0.23 $0.11
08/02/2022 Q2 -- -- -$0.13 -$0.22 $0.09
05/03/2022 Q1 -- -- -$0.20 -$0.23 $0.03
02/28/2022 Q4 -- -- -$0.15 -$0.15 -$0.00
11/09/2021 Q3 -- -- -$0.20 -$0.14 -$0.06
07/29/2021 Q2 -- -- -$0.13 -$0.25 $0.12
05/10/2021 Q1 -- -- -$0.66 -$0.12 -$0.54
02/17/2021 Q4 -- -- -$0.14 -$0.10 -$0.04
11/02/2020 Q3 -- -- -$0.08 -$0.20 $0.12
07/30/2020 Q2 -- -- -$0.22 -$0.27 $0.05
05/06/2020 Q1 -- -- -$0.24 -$0.20 -$0.04
02/25/2020 Q4 -- -- -$0.15 -$0.08 -$0.07
10/22/2019 Q3 -- -- -$0.02 -$0.07 $0.05
07/30/2019 Q2 -- -- -$0.05 -$0.09 $0.04
04/30/2019 Q1 -- -- -$0.05 -$0.07 $0.02
02/25/2019 Q4 -- -- -$0.08 -$0.15 $0.07
10/29/2018 Q3 -- -- -$0.12 -$0.21 $0.09
07/23/2018 Q2 -- -- -$0.18 -$0.27 $0.09
05/01/2018 Q1 -- -- -$0.27 -$0.25 -$0.02
02/27/2018 Q4 -- -- -$0.24 -$0.20 -$0.04
11/06/2017 Q3 -- -- -$0.21 -$0.21 $0.00
07/31/2017 Q2 -- -- -$0.22 -$0.25 $0.03
05/04/2017 Q1 -- -- -$0.24 -$0.24 -$0.01
03/01/2017 Q4 -- -- -- -- --
11/03/2016 Q3 -- -- -- -- --
08/03/2016 Q2 -- -- -- -- --
05/05/2016 Q1 -- -- -- -- --
03/10/2016 Q4 -- -- -- -- --
11/05/2015 Q3 -- -- -- -- --
08/13/2015 Q2 -- -- -- -- --

Veracyte Earnings Questions

  • How Much did Veracyte Generate in Revenue Last Quarter?

    Veracyte reported $114.5M worth of top line sales in its most recent quarter.

  • Did Veracyte Beat Earnings Last Quarter?

    Veracyte announced earnings per share of $0.09 which represents a miss of analyst forecast a $0.20 per share.

  • Is Veracyte Profitable?

    Veracyte reported $79.5M that represents $0.99 per share over the last quarter.

  • What is the Analyst Consensus for Veracyte EPS Next Year?

    Veracyte's earnings are forecast to grow from $0.31 per share to $1.01 per share next year representing an increase of 318.17%.

  • When is Veracyte's Earnings Date?

    Veracyte's next earnings date is August 6, 2025.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Palantir Crash?
Will Palantir Crash?

AI and data analytics software major Palantir (NASDAQ:PLTR) has been…

Is Target’s Dividend Worth Buying?
Is Target’s Dividend Worth Buying?

Retail giant Target (NYSE:TGT) has been through an extremely volatile…

Where Will AST SpaceMobile Be In 5 Years?
Where Will AST SpaceMobile Be In 5 Years?

Ever tried to send a text from the Nevada desert…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.6T
P/E Ratio: 41x

Buy
60
Is NVDA Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 49x

Sell
37
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Sell
49
RGC alert for Jun 17

Regencell Bioscience Holdings [RGC] is up 21.6% over the past day.

Buy
59
SYM alert for Jun 17

Symbotic [SYM] is down 1.69% over the past day.

Sell
43
TNXP alert for Jun 17

Tonix Pharmaceuticals Holding [TNXP] is down 4.52% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock